DP-QB-MYA-002
AXP000241.1 · Phage therapy
- Platform
- phage cocktail (non-engineered)
- Sponsor
- Alberta Health Services
Names
| Name | Type | Source |
|---|---|---|
| DP-QB-MYA-002 | preferred name, code | curator, ctgov |
Virus
- Role
- Phage
- Family
- Caudoviricetes
- Virus
- Mycobacterium abscessus bacteriophage (cocktail)
- Replication
- replicating
- Source
- evidence
Approvals
No regulatory approval recorded.
Clinical trials (1)
| Trial | Title | Status | Phase | Start | Primary completion | Enrolment | Conditions |
|---|---|---|---|---|---|---|---|
| NCT07429162 | Bacteriophage for Chronic Multidrug-Resistant Mycobacterium Abscessus Subsp. Abscessus Pulmonary Infection | Not yet recruiting | Phase 1 | 2026-07-02 | 2027-07-02 | 1 | Bacteriophage Therapy; Mycobacterium Abscessus Infection; Pulmonary Disease |
Recent changes
No changes recorded in its trials yet.
Notes
Phage cocktail against Mycobacterium abscessus subsp. abscessus pulmonary infection; phase 1 NCT07429162. Manufacturer not taken from a primary source.
How to cite
DP-QB-MYA-002 (AXP000241.1). The Abstractinator program registry, release 2026-11-17+2c46e992acfc. https://abstractinator.me/registry/AXP000241.html
Something wrong or missing? Suggest a correction (a GitHub issue; please link your evidence). Entry created 2026-11-11, updated 2026-11-11.